Clinical Trial Update: QDISS Stud: QD Isentress as Switch Strategy in Virologically Suppressed HIV-1 Infected-Patient [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating QD Isentress as a switch strategy in virologically suppressed HIV-1 patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Isentress (Raltegravir)

Snippet

Sponsor: Nantes University Hospital | Conditions: Virus-HIV | Phase 2 | Status: COMPLETED